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ABSTRACT  
Background: Obesity is strongly associated with esophageal adenocarcinoma (EAC), yet 
whether weight loss reduces the risk of EAC is unclear.  
Objectives: To test the hypothesis that the risk of EAC decreases following weight reduction 
achieved by obesity surgery. 5"
Setting: Nationwide register-based cohort study 
Methods: This study included a majority of individuals who underwent obesity surgery in 
Sweden in 1980-2012. The incidence of EAC following obesity surgery was compared to the 
incidence in the corresponding background population of Sweden by means of calculation of 
standardized incidence ratios (SIRs) with 95% confidence intervals (CIs). The risk of EAC 10"
after obesity surgery was also compared with the risk in non-operated obese individuals by 
means of multivariable Cox regression, providing hazard ratios (HRs) with 95% CIs, adjusted 
for potential confounders.    
Results: Among 34,437 study participants undergoing obesity surgery and 239,775 person-
years of follow-up, 8 cases of EAC occurred (SIR 1.6, 95% CI 0.7-3.2). No clear trend of 15"
decreased SIRs was seen in relation to increased follow-up time after surgery. The SIR of 
EACs (n=53) among 123,695 non-operated obese individuals (673,238 person-years) was 
increased to a similar extent as in the obesity surgery cohort (SIR=1.9, 95% CI 1.4-2.5). Cox 
regression showed no difference in risk of EAC between operated and non-operated 
participants (adjusted HR=0.9, 95% CI 0.4-1.9). 20"
Conclusions: The risk of EAC might not decrease following obesity surgery, but even larger 
studies with longer follow-up are needed to establish this association. 
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INTRODUCTION 25"
The incidence of adenocarcinoma of the esophagus (EAC), including the gastroesophageal 
junction, has increased rapidly in the Western world during the last four decades.(1, 2) The 
incidence of EAC in Sweden in 2013 was 10.9 cases per 100,000 men and 2.6 cases per 
100,000 women.(3) The increase in EAC parallels the globally increasing prevalence of 
obesity (body mass index [BMI] >30).(4) EAC appears to be strongly associated with 30"
increased BMI,(5, 6) and this association is seemingly linear.(7) Yet, it is uncertain whether 
weight loss counteracts EAC development. This uncertainty is explained by difficulties in 
assessing weight loss due to limited effects of lifestyle changes on BMI and variations in BMI 
over time, together with the need for large studies with long follow-up to assess this 
association. Obesity surgery might be a useful means of assessing the effects of weight loss, 35"
since on group level it results in substantial and persistent reduction in BMI and the weight 
loss is initiated at a specific date.(8) Some, but not all investigations have indicated a possibly 
decreased risk of cancer in general after successful obesity surgery;(9-12)"but any preventive 
effect of obesity surgery on the specific risk of developing EAC is unknown. A recent 
systematic review identified only 11 cases of EAC following obesity surgery in the literature, 40"
and these cases were mainly derived from case reports, prohibiting analysis of the risk of 
EAC.(13) The objective of this study was to test the hypothesis that the risk of EAC decreases 
following obesity surgery in a nationwide Swedish cohort study. 
 
  45"
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METHODS 
Study design 
This was a population-based cohort study including obese individuals aged between 18 and 
65 years who underwent obesity surgery in Sweden between January 1, 1980 and December 
31, 2012 (obesity surgery cohort). Obesity surgery was introduced in routine healthcare in 50"
Sweden in 1980 and individuals with a BMI ≥35 were considered potential surgical 
candidates. Two external comparison cohorts were used: the corresponding background 
Swedish population and obese individuals who did not undergo obesity surgery (obese non-
surgery cohort). The participants of both the obesity surgery cohort and the obese non-
operated cohort were identified from the Swedish Patient Registry; the obesity surgery cohort 55"
by a diagnosis code of obesity as well as an obesity surgery code, and the obese non-surgery 
cohort by a diagnosis code of obesity. The background population was derived from the 
Swedish Registry of the Total Population. All EACs occurring during follow-up of the 
cohorts, as well as those of the background population, were identified from the Swedish 
Cancer Registry. Any cases of EAC discovered at autopsy were excluded from all three 60"
cohorts to avoid ascertainment bias. Censoring of cohort members no longer at risk of EAC in 
the Cancer Registry due to death or emigration was enabled by data linkage to the Swedish 
Causes of Death Registry and the Registry of the Total Population, respectively. The 10-digit 
personal identity number, uniquely assigned to all Swedish residents upon birth or 
immigration, was used for all register linkages and for collection of medical records from 65"
patients who developed EAC after obesity surgery.(14) The study was approved by the 
Regional Ethical Review Board in Stockholm, Sweden. 
 
Data collection 
4"
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The Swedish Patient Registry was used to identify participants of the obesity surgery cohort 70"
and the obese non-operated cohort. This register was initiated in 1964 and contains 
information regarding in-hospital and outpatient specialist care in Sweden, including 
diagnoses and surgical procedures. The percentage of the Swedish population covered by this 
register was 85% in 1983 and 100% from 1987 onwards in terms of  in-hospital care, while 
the data on outpatient specialist care have been nationwide complete since 2001.(15) Studies 75"
have shown excellent validity of the data regarding the recorded information for both 
diagnoses and surgical procedures.(15, 16) Obesity was defined by the diagnosis codes 277, 
278A, and E66 in the International Classification of Diseases (ICD) versions 8, 9, and 10, 
respectively. Obesity surgery codes representing the most commonly used procedures, i.e. 
gastric bypass, vertical banded gastroplasty, and gastric banding (both open and laparoscopic 80"
techniques), were based on the Swedish and NOMESCO Classification of Surgical 
Procedures. The surgery codes were 4751 and 4753 before 1997 and JDF00, JDF01, JDF10, 
JDF11, JDF20 and JDF21 from 1997 onwards. 
 
The Swedish Cancer Registry was used to identify EAC, including the gastro-esophageal 85"
junction, using the ICD-7 codes 150 and 1511, and WHO/HS/CANC/24.1 histology code 096. 
This register contains data on all malignant tumors diagnosed in Sweden since 1958 and 
includes date of diagnosis, site of tumor (translated to ICD-7), and histological type of tumor. 
All physicians and pathologists are obliged to report all cancer cases, and the register has been 
verified to have 98% nationwide completeness in terms of EAC.(17) 90"
 
The Swedish Causes of Death Registry contains data regarding all deceased Swedish 
residents since 1952 and has a 99.2% completeness of cause-specific death.(18) Data from this 
register were used to censor individuals in the cohorts from follow-up at the date of death.  
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The Registry of the Total Population was used to identify the background population and to 
censor cohort members who emigrated during follow-up. This register has 100% nationwide 
completeness and is continuously updated.(19)  
 
Medical records were retrieved from the hospital departments for individuals in the obesity 100"
surgery cohort who developed EAC. These records were used to assess presenting symptoms, 
BMI, treatment and outcomes. 
 
Statistical analysis 
Standardized incidence ratio: Follow-up in the obesity surgery cohort was measured from the 105"
date of admission for obesity surgery, until the date of EAC, death, emigration, or end of the 
study period, whichever occurred first. Follow-up time for the obese non-surgery cohort was 
measured from the first date of obesity diagnosis until the date of obesity surgery, EAC, 
death, emigration, or end of the study period, whichever came first. The number of EACs in 
the obesity surgery cohort and in the obese non-surgery cohort was compared to their 110"
corresponding background population by means of calculation of standardized incidence 
ratios (SIRs) and 95% confidence intervals (CIs). SIRs were calculated by dividing the 
observed number of EACs in the obesity surgery cohort and the obese non-surgery cohort by 
the expected number of EACs using direct standardization. The expected number of EACs 
was calculated separately for the obesity surgery cohort and the obese non-surgery cohort, 115"
using the incidence of EAC in the background population of the corresponding age 
(categorized in 10-year intervals), sex (male or female), and calendar year (categorized by 
each year) distributions as the members of these cohorts, multiplied by the person-time in 
each cohort. We also performed predefined analyses stratified for sex (male and female), age 
6"
"
at inclusion (18-41 years and 42-65 years, a cut-off chosen as half of the possible age range at 120"
inclusion [18-65 years]), and follow-up time after surgery or obesity diagnosis (≤5 years, >5-
10 years, and >10 years).  
 
Cox regression: The risk of EAC in the obesity surgery cohort was also directly compared 
with the risk of EAC in the obese non-surgery cohort by means of multivariable Cox 125"
regression analysis, providing hazard ratios (HRs) and 95% CIs. The HRs were adjusted for 
age (continuous variable), sex (male or female), calendar period (continuous variable), years 
of formal education (≤9 years, 10-12 years, or >12 years), history of chronic obstructive 
pulmonary disorder (yes or no, proxy for tobacco smoking), and history of diabetes mellitus 
(yes or no). Since gastric bypass is known to improve GERD, while this effect is less clear 130"
following restrictive procedures (vertical banded gastroplasty and gastric banding),(20) we also 
conducted analyses for these procedures separately. To evaluate the proportional hazard 
assumption, the correlation between Schoenfeld residuals and the ranking of individual failure 
times was calculated for each covariate in the unadjusted and adjusted models. None of the 
covariates had a statistically significant association with these residuals or failure time (p-135"
value >0.05), which supports the proportional hazards assumption. All statistical analyses 
were conducted using the statistical software SAS, version 9.4 (SAS Institute Inc., Cary, NC, 
USA). 
 
  140"
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RESULTS 
Participants 
The obesity surgery cohort included 34,437 unique individuals and 239,775 person-years at 
risk. Gastric bypass was the dominant procedure (n=25,536, 74%), followed by vertical 
banded gastroplasty (n=4,889, 14%) and gastric banding (n=4,012, 12%). The obese non-145"
surgery cohort included 123,695 unique individuals and 673,238 person-years at risk. The 
distribution of age, follow-up time, year of inclusion, education level, chronic obstructive 
pulmonary disorder and diabetes were similar in these two cohorts, while there were fewer 
men in the obesity surgery cohort (24% versus 33%) (Table 1). The maximum follow-up time 
in both cohorts was 33 years.  150"
In the obesity surgery cohort, 8 cases of EAC occurred, including 4 cases following gastric 
banding (3 open and 1 laparoscopic), 2 cases following open vertical banded gastroplasty and 
2 cases following open gastric bypass (Tables 1 and 2). Seven patients (88%) were male, and 
the median age at EAC diagnosis was 63.5 years. The EACs were diagnosed within median 
9.2 years after obesity surgery. The mean BMI at EAC diagnosis was 34.4 (range 25-44) and 155"
5 of the 7 patients were still obese (BMI >30) where BMI was available. The mean BMI loss 
following obesity surgery was 6.3 for the 6 patients where pre-surgery BMI was available. 
The EAC patients presented with dyspepsia, nausea, melena or dysphagia (2 patients each), 
anemia, weight loss, hematochezia, or vomiting (1 patient each).  
In the obese non-surgery cohort, 53 cases of EAC occurred, including 40 males (75%), with a 160"
median age of 60.0 years and median 5.9 years latency between obesity and EAC diagnosis 
(Table 1).  
The rate of EAC following gastric banding or vertical banded gastroplasty (grouped) was 3.9 
cases per 100,000 persons and year, and the rate of EAC following gastric bypass was 2.0 
8"
"
cases per 100,000 persons and year. The overall rate of EAC in the background population 165"
during the follow-up period was 5.4 per 100,000 persons and year. 
 
Risk of esophageal adenocarcinoma 
Obesity surgery cohort 
The overall SIR of EAC was 1.6 (95% CI 0.7-3.2) in the obesity surgery cohort (Table 3). 170"
The SIR did not change significantly when stratifying for follow-up time after surgery. The 
point estimates of EAC were higher for men than women and for older individuals than 
younger, but the confidence intervals overlapped (Table 3).  
 
Obese non-surgery cohort 175"
The overall SIR was 1.9 (95% CI 1.4-2.5) in the obese non-surgery cohort (Table 3). The 
SIRs were stable over time after obesity diagnosis. The point estimates were higher among 
older than younger participants, but without statistical significance, and no sex differences 
were seen (Table 3). 
 180"
Obesity surgery cohort compared to the obese non-surgery cohort 
The crude HR indicated a decreased HR of EAC comparing obese individuals who underwent 
obesity surgery with obese individuals not undergoing such surgery (unadjusted HR 0.4, 95% 
CI 0.2-0.9), but the HR approached 1 after multivariable adjustment (adjusted HR 0.9, 95% 
CI 0.4-1.9) (Table 4). Adjusted HRs following vertical banded gastroplasty or gastric banding 185"
(6 cases) was 1.0 (95% CI 0.4-2.6), and 0.5 (95% CI 0.1-2.3) after gastric bypass (2 cases). 
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DISCUSSION 
This study did not provide evidence for the hypothesis of a decreased risk of EAC after 
obesity surgery. The point estimates of EAC were increased after obesity surgery compared to 190"
the background population, and similar to non-operated obese individuals.  
 
The nationwide coverage with complete follow-up of a large obesity surgery cohort that was 
compared with the corresponding background population and non-operated obese are among 
the methodological strengths of the study. However, despite a substantial number of cohort 195"
members, the main limitation is the low statistical precision, which was due to the low 
number of new EACs and a limited long-term follow-up of the operated patients.  
This is nevertheless the largest study to date which provides the highest number of EAC cases 
described in the literature, and it is to the best of our knowledge, the first controlled study on 
the topic. There is a risk of selection bias in the obese non-surgery cohort, since only a limited 200"
portion of all obese patients received a diagnosis code for obesity in the Patient Registry, 
while for the obesity surgery cohort the obesity diagnosis was the reason for the surgery. 
Thus, the obesity surgery cohort might not be entirely comparable to the obese non-surgery 
cohort regarding potential confounding factors. However, the adjustment for confounders 
changed the point estimates from 0.4 to 0.9, reducing some of this concern. Other limitations 205"
were the lack of data on BMI.(21) However, another study of obesity surgery in Sweden which 
included a portion of the participants of the present study, found an average decrease in BMI 
10 years following surgery (n=2010) from 41.9 to 35.3 (15.7%), compared to an increase 
from 39.9 to 40.8 (2.3%) in the non-surgery group (n=2037).(22) This illustrates the great 
difference in weight change in the obesity cohort and the obese non-surgery cohort of the 210"
present study, although it also suggests that patients may still remain obese, albeit to a lesser 
degree, following obesity surgery. However, the lack of individual BMI data meant that we 
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could not separate out patients with "successful" obesity surgery (i.e., BMI <30). Finally, we 
did not have information on Barrett´s esophagus or gastroesophageal reflux disease, but these 
conditions might be seen as variables in the pathway between the association between BMI 215"
and weight loss and EAC, thus the lack of this information might not be a major concern. 
  
Obesity surgery might be seen as a human model for research addressing the consequences of 
weight loss, since this surgery is clearly more effective than non-surgical interventions for 
weight loss, and the weight loss starts from a certain date.(8, 23) Yet, the available literature 220"
assessing the risk of EAC after obesity surgery is limited. Only 11 patients with EAC 
occurring after obesity surgery are known in the literature.(13) The mean age at EAC diagnosis 
in these patients was lower (54 years), and the mean latency period between obesity surgery 
and EAC diagnosis was shorter (5.5 years) than in the present study (63 years and 9.2 years, 
respectively).(13) The only previous cohort study included 2,875 individuals following obesity 225"
surgery and 3 cases of high-grade dysplasia or EAC (0.1%), but that study did not include any 
control group, hence relative risk estimates were not possible to calculate.(24)  
 
There are other mechanisms besides weight loss that might influence the association between 
obesity surgery and EAC. Severe obesity typically develops over many years, and might 230"
result in a persistently increased abdominal pressure, leading to long-term and severe 
gastroesophageal reflux disease, which might be irreversible at the time of obesity surgery. It 
is also possible that the anatomic changes following obesity surgery might influence the 
future risk of EAC, although the extent and direction of any such influence is uncertain. 
Gastric bypass can reduce symptoms of gastroesophageal reflux disease as well as acid 235"
exposure in patients with Barrett’s esophagus,(25, 26) and there are reports of regression of 
Barrett’s esophagus following gastric bypass.(27) However, there are also studies of bile reflux 
11"
"
in the gastric pouch following gastric bypass,(28, 29) which is a risk factor for EAC.(30-32) For 
gastric banding and vertical-banded gastroplasty, some studies have shown an increased risk 
of gastroesophageal reflux disease and Barrett’s esophagus,(33) risk of food and gastric acid 240"
stasis causing chronic mucosal irritation,(34, 35) and local irritation due to the presence of the 
gastric band.(36) A study following patients up to 18 months after gastric banding found an 
increased risk of esophageal dysmotility.(37) Moreover, although most individuals lose weight 
after obesity surgery, they rarely become non-obese (BMI <30). In the recent systematic 
review and in the present study, BMI at the time of EAC diagnosis was typically ≥30,(24, 38, 39) "245"
which could partly explain the possible lack of a decreased risk of EAC compared to the 
background population. We attempted to assess the risk of EAC following the different types 
of obesity surgery procedures, and these results indicated no obvious differences between the 
procedures, although the statistical power was low.  
 250"
In a clinical setting, this study indicates that patients following obesity surgery comprise a 
patient group that remains at increased risk of EAC. This in turn indicates a need for 
awareness, especially since the symptoms might be non-characteristic or attributed to the 
obesity surgery itself, which could lead to delayed diagnosis and treatment.(40)  
 255"
CONCLUSIONS 
This population-based nationwide Swedish cohort study of nearly 0.25 million person-years at 
risk did not find evidence of any decreased risk of EAC following obesity surgery when 
compared to the background population or non-operated obese individuals. However, the 
results must be interpreted cautiously due to the limited statistical power, and larger cohort 260"
studies with longer follow-up are warranted. 
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Table 1. Characteristics of an obesity surgery cohort and an obese non-surgery cohort, identified in 
the Swedish Patient Registry in 1980-2012, and the distribution of esophageal adenocarcinoma (EAC) 
in these cohorts.  
 Obesity surgery 
Number=34,437 
Obese non-surgery 
Number=123,695 
Person-years of follow-up 239,775 673,238 
Age at inclusion, median years (IQR*) 40 (33-48) 43 (32-54) 
Male sex, number (%) 8,243 (24) 40,782 (33) 
Year of inclusion, median (IQR*) 2009 (2002-2011) 2007 (2002-2010) 
Follow-up time in years, median (IQR*) 3.7 (1.8-9.7) 3.5 (1.3-7.3) 
Educational level     <9 years, number (%) 6,786 (20) 30,440 (25) 
                                10-12 years, number (%) 20,650 (60) 64,519 (53) 
                                 >12 years, number (%) 6,873 (20) 26,932 (22) 
Chronic obstructive pulmonary disorder, number (%) 436 (1) 2,963 (2) 
Diabetes, number (%) 4,536 (13) 18,997 (15) 
Cases of EAC (number) 8 53 
   Age at cancer diagnosis, median years (IQR*) 63.5 (61.5-67.5) 60.0 (56.0-66.0) 
   Time after inclusion, median years (IQR*) 9.2 (6.6-15.0) 5.9 (2.3-10.1) 
   Male, number (%) 7 (88) 40 (75) 
 
* Interquartile range 
Table 2. Clinical characteristics of individuals developing esophageal adenocarcinoma (EAC) following obesity surgery.  
Patient  Sex Year of 
obesity 
surgery 
Age at 
obesity 
surgery 
Obesity surgery 
technique 
Pre-
surgery 
BMI* 
ΔBMI*  BMI* 
at EAC  
Year of 
EAC 
diagnosis 
Age at 
EAC 
diagnosis 
Years 
between 
obesity 
surgery 
and EAC 
Symptoms Tumor 
stage 
Years 
of 
follow-
up after 
EAC 
Treatment Outcome 
1 Female 1998 40 Open vertical 
banded gastroplasty 
42 5 37 2007 51 10 Dyspepsia, 
nausea 
TXN3M1 0.1 None Died of 
EAC 
2 Male 1998 52 Open vertical 
banded gastroplasty 
34 3 31 2009 63 11 Melena, 
anemia 
TXNXM1 1.2 CTx# + 
RTx┼ 
Died of 
EAC 
3 Male 1985 49 Open gastric 
banding 
46 7 39 2006 71 22 Dysphagia, 
weight loss 
T1N0M0 8.7 CTx# + 
surgery 
Cured 
4 Male 1986 55 Open gastric 
banding 
Missing  Missing Missing 1994 64 9 Asymptomatic T1N0M0 0.6 Surgery Died of 
EAC 
5 Male 1988 54 Open gastric 
banding 
Missing  Missing
  
44  2007 74 19 Nausea, 
vomiting 
TXN3M1 0.1 None Died of 
EAC 
6 Male 2000 56 Laparoscopic gastric 
banding 
38 0 38 2009 64 8 Melena, 
hematochezia 
T3N0M0 5.2 CTx# + 
RTx┼ + 
surgery 
Cured 
7 Male 2006 59 Open gastric bypass 35 10 25 2011 65 5 Dyspepsia T4bN0M0 1.8 CTx# + 
surgery 
Died of 
EAC 
8 Male 2008 56 Open gastric bypass 40 13 27 2012 60 4 Dysphagia T3N2M0 2.5 CTx# + 
surgery  
Died of 
EAC 
 
* Body mass index, EAC esophageal adenocarcinoma, # chemotherapy, ┼ radiotherapy 
Table 3. Standardized incidence ratios (SIR) and 95% confidence intervals (CIs) of 
esophageal adenocarcinoma (EAC) after obesity surgery and in non-operated obese 
participants compared with their corresponding background population. 
 Obesity surgery cohort  Obese non-surgery cohort 
Model EAC 
(number) 
SIR (95% CI) EAC 
(number) 
SIR (95% CI) 
All 8 1.6 (0.7-3.2) 53 1.9 (1.4-2.5) 
Sex     
   Male 7 2.4 (0.9-4.9) 40 1.9 (1.3-2.6) 
   Female 1 0.5 (0.0-2.8) 13 1.9 (1.0-3.3) 
Age at inclusion     
   18-41 years 1 0.9 (0.0-5.3) 7 3.5 (1.4-7.2) 
   42-65 years 7 1.8 (0.7-3.7) 46 1.8 (1.3-2.3) 
Follow-up      
   ≤ 5 years 2 1.3 (0.2-4.8) 23 1.8 (1.2-2.7) 
   > 5-10 years 3 3.1 (0.6-9.1) 16 2.1 (1.2-3.4) 
   > 10 years 3 1.2 (0.2-3.5) 14 1.8 (1.0-3.0) 
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